Market research
73C.F Concert Pharmaceuticals, Inc
F EUR Healthcare
Latest close
Loading market data…
Test a moving-average rule with historical data.
- Market cap
- 381M
- P/E ratio
- Not available
- Analyst target
- 15.33
- Dividend yield
- 0.0%
- Beta
- 0.52
Profile
Company facts
- Exchange
- F
- Currency
- EUR
- Sector
- Healthcare
- Industry
- Biotechnology
- ISIN
- US2060221056
- Market cap
- 381M
- P/E ratio
- Not available
- Analyst target
- 15.33
- Dividend yield
- 0.0%
- Beta
- 0.52
About
About Concert Pharmaceuticals, Inc
Concert Pharmaceuticals, Inc. operates as a clinical stage biopharmaceutical company that develops novel small molecule drugs for the treatment of autoimmune diseases. The company's lead product candidate is CTP-543, which is in Phase III clinical trial for the treatment of alopecia areata, a serious autoimmune dermatological condition. It has strategic collaborations with Avanir Pharmaceuticals, Inc.; Jazz Pharmaceuticals, Inc.; Cipla Technologies; and Processa Pharmaceuticals. The company was incorporated in 2006 and is headquartered in Lexington, Massachusetts. As of March 6, 2023, Concert Pharmaceuticals, Inc. operates as a subsidiary of Sun Pharmaceutical Industries Limited.
Visit company websiteCommunity
Investor discussion
1 comment
Sign in to join the 73C.F discussion.
5 years, 4 months ago
Concert Pharmaceuticals, Inc is currently in a long term downtrend where the price is trading 51.6% below its 200 day moving average.
From a valuation standpoint, the stock is 98.5% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 19.4.
Concert Pharmaceuticals, Inc's total revenue sank by 46.2% to $7K since the same quarter in the previous year.
Its net income has dropped by 9.3% to $-22M since the same quarter in the previous year.
Finally, its free cash flow fell by 6.6% to $-16M since the same quarter in the previous year.
Based on the above factors, Concert Pharmaceuticals, Inc gets an overall score of 1/5.